P2Y12 inhibitors, such as clopidogrel, prasugrel, and ticagrelor, have emerged as pivotal in mitigating adverse cardiovascular outcomes following revascularization in coronary artery disease (CAD). The gene discussed is P2RY12; the disease is coronary artery disorder.